Pharma News

The kindred nature of martial arts and drug development

This audio is auto-generated. Please let us know if you have feedback.

Karate is, in many ways, a solitary pursuit. Alone in the sparring arena with only an opponent and no one to hide behind, a martial artist relies solely on training and character to succeed.

“I guess that’s the same as being CEO — you’re quite exposed, and you have to be comfortable with that level of exposure,” said Richard Godfrey, CEO of IRLAB Therapeutics, a Swedish clinical-stage biotech specializing in the development of drugs for Parkinson’s disease and other disorders of the brain. “It’s quite a lonely place to be very often. A lot of eyes on you. A lot of people have high expectations of you.”

In fact, Godfrey sees many parallels between his career as a leader and his lifelong passion for karate.

“You need to have confidence, humility (and) tremendous integrity,” he said.

Godfrey took on the role of CEO for IRLAB Therapeutics in July 2022 after more than two decades of leadership roles in the international biotech and pharmaceutical industry, including stints at Catalent Pharma Solutions and BerGenBio.

“I was keen to work for a company that was clinical-stage but also had a discovery engine and was working in areas of significant unmet need,” he said.

IRLAB Therapeutics certainly ticks all those boxes. The company’s work is rooted in research of Professor Arvid Carlsson, whose discoveries with the neurotransmitter dopamine and its effects in Parkinson’s disease earned him the Nobel Prize in Physiology or Medicine in 2000. Three of IRLAB’s co-founders, who are also members of its management team, worked in Carlsson’s research group.

Today, they’re working to translate those groundbreaking discoveries into drugs that could have a transformative impact on patients.

Richard Godfrey, CEO, IRLAB Therapeutics

Richard Godfrey, CEO, IRLAB Therapeutics

Permission granted by IRLAB


Improving quality of life

Carlsson’s research showed that Parkinson’s disease symptoms are caused by a deficit of the neurotransmitter dopamine in the brain — an issue IRLAB’s drugs were developed to counteract. The company just concluded a phase 2b study for its drug candidate mesdopetam, which aims to treat levodopa-induced dyskinesias (LIDs) — severe forms of involuntary movements in Parkinson’s disease patients. Godfrey said he expects those results this month.

“In drug discovery and drug development, you have to have patience. You have to have a very, very acute attention to detail and getting it right.”

Richard Godfrey

CEO, IRLAB Therapeutics

In 2021, IRLAB licensed the exclusive global development and commercialization rights for mesdopetam to specialty pharma company Ipsen, which will be responsible for phase 3 preparatory activities as well as all remaining clinical development and worldwide commercialization, the company said on its website.

Another drug in its pipeline is pirepemat, which it is developing to improve balance and reduce falls in people with Parkinson’s disease. It’s currently in a phase 2b study expected to yield results by the end of 2023.

Parkinson’s mechanisms are largely a mystery and there is no cure, so current treatments focus on managing symptoms. Both mesdopetam and pirepemat address debilitating symptoms of the disease that have stymied drug developers for decades. There are currently only a handful of treatments for LIDs, but mesdopetam’s phase 2a study reported an additional 2.8 hours of what’s called “good on-time” — or time when a medication is working effectively.

“Even one hour of additional good on-time and reducing the bad on-time would be quite transformative for a patient,” Godfrey said.

A 2022 study in the journal Neurology showed that hour increases in good on-time was “significantly associated” with positive outcomes, such as fewer falls, and greater reports of independence for activities of daily living in patients with advanced Parkinson’s.

Meeting unmet needs

While the approved treatment landscape for LIDs is thin, it’s nonexistent for improving balance and reducing falls.

“We’re the first company in the world to develop a drug specifically for postural instability and falls frequency,” Godfrey said.

Early results for pirepemat are also promising. Godfrey said their preclinical and phase 2a data saw a 35% improvement in balance and 53% reduction in falls frequency, as well as major improvements in patient apathy and caregiver distress.

“It’s transformative for the patient’s quality of life,” Godfrey said.

Source link
#kindred #nature #martial #arts #drug #development

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *